Protagonist Therapeutics, Inc. (PTGX) Stock Forecast
PTGX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.79 / 5 from 14 analysts
- Price target
- $178.21 average of analyst targets
- Upside to target
- +38.4% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $2.19
- 52-week range
- $73.50 – $158.62
PTGX analyst ratings
14 analystsNumber of analysts at each rating.
PTGX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PTGX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.53 | $0.13 | $3.40 | −$0.62 | +508.4% | 12 |
| Current fiscal year (2026) | $4.66 | $3.52 | $5.74 | −$2.05 | +327.1% | 13 |
| Next fiscal year (2027) | −$0.15 | −$2.80 | $4.75 | $4.66 | −103.3% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PTGX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $232.0M | $82.0M | $287.0M | +4,824.5% | 12 |
| Current fiscal year (2026) | $541.6M | $428.5M | $586.5M | +1,077.1% | 13 |
| Next fiscal year (2027) | $211.3M | $67.8M | $581.6M | −61.0% | 13 |
PTGX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PTGX revenue: reported and forecast
PTGX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.25 | $2.49 | $2.60 | $2.60 | $2.53 | +12.4% | 6 up · 3 down |
| Current fiscal year (2026) | $4.21 | $4.75 | $4.79 | $4.79 | $4.66 | +10.5% | 9 up · 3 down |
| Next fiscal year (2027) | −$0.55 | −$0.14 | −$0.20 | −$0.20 | −$0.15 | −72.0% | 7 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PTGX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PTGX beat in 7 of 12.
What analysts expect from PTGX
14 analysts cover Protagonist Therapeutics; their consensus rating is strong buy (4.79 on a 1–5 scale, where 5 is a strong buy). The average price target is $178.21, 38.4% above the latest close of $128.75. Analysts expect earnings of $4.66 per share for 2026, +327.1% from a year earlier. For 2027 the average estimate is −$0.15 per share on revenue of $211.3 million. Protagonist Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: PTGX income statement, PTGX key metrics, PTGX chart. See the PTGX stock overview for the latest quote and news.
PTGX forecast FAQ
What is Protagonist Therapeutics's price target?
The average analyst price target for Protagonist Therapeutics is $178.21, 38.4% above the latest close of $128.75.
Is Protagonist Therapeutics a buy, hold or sell?
Of 14 analysts covering Protagonist Therapeutics, 11 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Protagonist Therapeutics's EPS forecast?
Analysts forecast $4.66 per share for 2026 (range $3.52 to $5.74); for 2027 the estimate is −$0.15.
What is Protagonist Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $541.6 million, growth of 1,077.1%; for 2027 it is $211.3 million.
When does Protagonist Therapeutics report earnings?
Protagonist Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $2.19.
Does Protagonist Therapeutics usually beat earnings estimates?
Protagonist Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.